MSD and LaNova Medicines Enter Exclusive Global License Agreement for Novel Cancer Therapy, LM-299

Promising CAR T Cell Therapies from BMS and Cabaletta Bio Show Potential for Durable Remission in Severe Lupus

FDA Grants Accelerated Approval to PTC Therapeutics' KEBILIDI™, the First Gene Therapy for AADC Deficiency in the U.S.

Association for Molecular Pathology Publishes Joint Consensus Report on SARS-CoV-2 Genomic Surveillance for Hospitals and Public Health Laboratories

Philips India Unveils Advanced Azurion Imaging System to Revolutionize Cardiac and Neurovascular Care

Tempus AI Study Highlights Benefits of Dual RNA and DNA Sequencing for Advanced Lung Cancer

Ontada and Datavant Partner to Expand Access to Real-World Oncology Data for Accelerated Cancer Innovation

Tempus AI and Flatiron Health Partner to Integrate Genomic Testing into OncoEMR for Enhanced Oncology Care

Flare Therapeutics and Roche Forge Strategic Partnership to Discover Precision Oncology Therapies Targeting Transcription Factors

FDA Approves Autolus’s CAR-T Therapy Aucatzyl for Relapsed or Refractory B-ALL in Adults

Biosimilars: Expanding Access to Precision Medicine through Affordable Biologic Therapies

IDEAYA Biosciences Secures Exclusive Worldwide License for Biocytogen’s BsADC Program IDE034 for Solid Tumor Treatment

Seer and Thermo Fisher Scientific Announce Strategic Collaboration to Advance Proteomics with Integrated Platform Solution

SystImmune Secures FDA Clearance for IND Application of Novel ADC Therapy BL-M17D1 for Advanced Solid Tumors

Medicare Expands Coverage for Adaptive Biotechnologies' clonoSEQ® MRD Test to Include Mantle Cell Lymphoma

Home
/
update
/
details

Cepheid and Fleming Initiative Join Forces to Combat Antimicrobial Resistance

NextEdge Admin

26 Sep 2024

1 min 53 sec

Cepheid,Fleming Initiative,antimicrobial resistance

Danaher subsidiary Cepheid has partnered with the Fleming Initiative to address antimicrobial resistance. The Fleming Initiative, a global collaboration led by Imperial College Healthcare NHS Trust and Imperial College London, brings together researchers, policymakers, clinicians, behavioral experts, and partners to develop equitable solutions for combating antimicrobial resistance worldwide.

This partnership will focus on collaborative scientific and clinical research aimed at promoting the use of in vitro diagnostics to support antimicrobial stewardship programs. These programs are designed to encourage responsible antibiotic use and curb the rise of drug-resistant infections.

The initial efforts will center on three key areas: enhancing screening for carbapenemase-producing Enterobacteriaceae (CPE) to enable earlier detection of critical infections, implementing community-based testing and care pathways for acute respiratory infections, and accelerating a precision medicine approach for sepsis to better identify and treat patients based on their specific sepsis response.

Cepheid President Vitor Rocha emphasized the importance of accurate diagnostics in reducing unnecessary antibiotic use, urging individuals to request diagnostic tests to determine the source of an infection before starting antibiotics. Cepheid is the first diagnostics company to join the Fleming Initiative in this global effort to combat antimicrobial resistance.